A larger proportion of patients with gout had a therapeutic response at six months when treated with methotrexate and pegloticase than with pegloticase alone, according to results from the multi-center, open-label MIRROR (methotrexate to increase response rates in patients with uncontrolled gout receiving KRYSTEXXA) study, recently published in the Journal of Rheumatology.1 The MIRROR study…
Patients who have undergone a kidney transplant and have high levels of serum uric acid symptomatic gout may benefit from treatment with pegloticase, according to a recent study.
Experts compare using ultrasound and dual-energy computed tomography (DECT) scan when diagnosing likely gout patients, and discuss the latest insights into the intersection between gout and cardiovascular disease.
A presentation at ACR Convergence 2021 discussed the 2020 ACR Guideline for the Management of Gout, the latest information on the risk of cardiovascular death associated with febuxostat and the use of pegloticase for patients with gout.
Dr. Lisa Stamp helps filter the noise to get to the key insights from the research abstracts on gout presented at ACR Convergence 2021.
Gout is a common form of inflammatory arthritis, affecting ~9.2 million adults (3.9%) in the U.S. The good news: The etiology of gout is well understood, and effective, inexpensive medications exist to treat it. However, gaps in quality of care persist. Below, explore selected content from The Rheumatologist’s collection of research reviews, case reports and…
Gout is the most common type of inflammatory arthritis in adults, and it typically occurs in men over the age of 50. When gout presents in younger patients or in women, this should warrant consideration of secondary causes. We describe an unusual genetic cause of tophaceous gout in a young, premenopausal woman. Case Report In…
Pegloticase is safe and effective to treat patients with refractory gout who are undergoing dialysis, according to recently presented research.
Short-term concomitant use of MMF with pegloticase was generally well tolerated in this proof-of-concept study. It was associated with a statistically significant and clinically meaningful impact on the proportion of subjects achieving and maintaining a sUA ≤6 mg/dL at 24 weeks. See the abstract with bonus video discussing the validation of proposed remission and completion criteria for the treatment of gout.